Lakewood-Amedex Biotherapeutics (LABT) Stock Price, News & Analysis

Company Overview

Lakewood-Amedex Biotherapeutics, Inc. is a biotechnology company focused on developing anti-infective therapies and products. Its research has centered on broad-spectrum antimicrobial compounds designed to address bacterial, viral and fungal pathogens while supporting topical and localized treatment applications.

The company’s development portfolio has included NVC-422, also known as an Aganocide compound. NVC-422 has been evaluated for potential uses in areas such as skin infections, wound care and other conditions where topical antimicrobial treatment may be appropriate. Lakewood-Amedex has also pursued related applications for its anti-infective technology.

The company is associated with operations in the United States, including Florida. Publicly available information about its current leadership, commercial operations and geographic reach is limited, and the company’s product candidates may remain subject to clinical, regulatory and commercial development requirements.

Key Stats

• Today's Range: $0.92 to $1.09
• 50-Day Range: $0.99 to $3.41
• 52-Week Range: $0.92 to $98.20
• Volume: 1.24 million shs
• Average Volume: 2.37 million shs
• Market Capitalization: $2.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Lakewood-Amedex Biotherapeutics Stock Analysis - MarketRank™

Lakewood-Amedex Biotherapeutics scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Lakewood-Amedex Biotherapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Lakewood-Amedex Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -73.39%

Earnings Growth

Earnings for Lakewood-Amedex Biotherapeutics are expected to decrease by -73.39% in the coming year, from $4.96 to $1.32 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lakewood-Amedex Biotherapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lakewood-Amedex Biotherapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.36% of the float of Lakewood-Amedex Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lakewood-Amedex Biotherapeutics has a short interest ratio ("days to cover") of 0.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lakewood-Amedex Biotherapeutics has recently decreased by 13.74%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lakewood-Amedex Biotherapeutics does not currently pay a dividend.

Dividend Growth

Lakewood-Amedex Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.25

News Sentiment

Lakewood-Amedex Biotherapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Lakewood-Amedex Biotherapeutics this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for LABT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

1 people have added Lakewood-Amedex Biotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lakewood-Amedex Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.35% of the stock of Lakewood-Amedex Biotherapeutics is held by insiders.

Percentage Held by Institutions

Lakewood-Amedex Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:LABT
• CIK: 2079272
• Web: lakewoodamedex.com
• Phone: (941) 225-2515
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 0.20
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.70
• Quick Ratio: 7.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,370,000
• Free Float: 2,243,000
• Market Cap: $2.35 million
• Optionable: N/A
• Beta: N/A